RLS
MCID: RST001
MIFTS: 54

Restless Legs Syndrome (RLS) malady

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Restless Legs Syndrome

Aliases & Descriptions for Restless Legs Syndrome:

Name: Restless Legs Syndrome 12 50 25 51 52 42 14 69
Restless Leg Syndrome 50 25
Willis-Ekbom Disease 12 25
Wed 12 25
Wittmaack-Ekbom Syndrome 12
Willis Ekbom Disease 50
Ekbom's Syndrome 25
Ekbom Syndrome 25
Restless Legs 41
Rls 25

Classifications:



External Ids:

Disease Ontology 12 DOID:0050425
ICD10 33 G25.81
ICD9CM 35 333.94
MeSH 42 D012148
NCIt 47 C84501
SNOMED-CT 64 32914008 393579008
UMLS 69 C0035258

Summaries for Restless Legs Syndrome

NIH Rare Diseases : 50 restless legs syndrome (rls) is a neurological condition that causes an irresistible urge to move the legs. the movement is triggered by strange or uncomfortable feelings, which occur mostly while the affected person is sitting or lying down and are worse at night. movement (i.e. kicking, stretching, rubbing, or pacing) makes the discomfort go away, at least temporarily. many people with restless legs syndrome also have uncontrollable, repetitive leg movements that occur while they are sleeping or while relaxed or drowsy. researchers have described early-onset and late-onset forms of restless legs syndrome. the early-onset form begins before age 45 and progresses slowly. the late-onset form begins after age 45, and its signs and symptoms tend to worsen more rapidly. rls likely results from a combination of genetic and environmental factors, many of which are unknown. the syndrome may also be classified in several types (rls1, rls2, rls3, rls4, rls5, rls6, rls7) according to the location in specific chromosomes of some of the genes that are associated with an increased risk (susceptibility) to have the syndrome.  treatment is based on the signs and symptoms present in each person. last updated: 5/5/2017

MalaCards based summary : Restless Legs Syndrome, also known as restless leg syndrome, is related to restless legs syndrome 2 and restless legs syndrome 1, and has symptoms including back pain, headache and pain. An important gene associated with Restless Legs Syndrome is BTBD9 (BTB Domain Containing 9), and among its related pathways/superpathways are Circadian rythm related genes and DARPP-32 Phosphorylation. The drugs Benzocaine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and brain, and related phenotype is nervous system.

Disease Ontology : 12 A central nervous system disease characterized by throbbing, pulling creeping or other unpleasant sensations in the legs and the irresistible urge to move them.

Genetics Home Reference : 25 Restless legs syndrome is a neurological condition that causes an irresistible urge to move the legs. The movement is triggered by strange or uncomfortable feelings, often described as crawling, pulling, or itching, deep within both legs. The feelings usually occur while the affected person is sitting or lying down and are worse at night. Movement, such as kicking, stretching, rubbing, or pacing, make the discomfort go away, at least temporarily. The unpleasant feelings and the resulting need to move the legs often make it difficult for an affected person to fall asleep or stay asleep.

MedlinePlus : 41 restless legs syndrome (rls) causes a powerful urge to move your legs. your legs become uncomfortable when you are lying down or sitting. some people describe it as a creeping, crawling, tingling, or burning sensation. moving makes your legs feel better, but not for long. rls can make it hard to fall asleep and stay asleep. in most cases, there is no known cause for rls. in other cases, rls is caused by a disease or condition, such as anemia or pregnancy. some medicines can also cause temporary rls. caffeine, tobacco, and alcohol may make symptoms worse. lifestyle changes, such as regular sleep habits, relaxation techniques, and moderate exercise during the day can help. if those don't work, medicines may reduce the symptoms of rls. most people with rls also have a condition called periodic limb movement disorder (plmd). plmd is a condition in which a person's legs twitch or jerk uncontrollably, usually during sleep. plmd and rls can also affect the arms. nih: national heart, lung, and blood institute

NINDS : 51 Restless legs syndrome (RLS) is characterized by unpleasant sensations in the legs and an irresistible urge to move them. Individuals affected with the disorder often describe the sensations as throbbing, polling, or creeping. The sensations range in severity from uncomfortable to irritating to painful. Symptoms commonly occur in late afternoon or evening and are most severe at night, when the person is resting. Moving the legs or walking typically relieves the discomfort but the symptoms often recur. RLS is both a sleep and a neurological sensory disorder.

Wikipedia : 71 Restless legs syndrome (RLS) is a disorder that causes a strong urge to move one\'s legs. There is often... more...

Related Diseases for Restless Legs Syndrome

Diseases related to Restless Legs Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 135)
id Related Disease Score Top Affiliating Genes
1 restless legs syndrome 2 12.4
2 restless legs syndrome 1 12.3
3 restless legs syndrome 6 12.3
4 restless legs syndrome 3 12.3
5 restless legs syndrome 7 12.3
6 restless legs syndrome 5 12.3
7 restless legs syndrome 4 12.3
8 restless legs syndrome 8 12.3
9 machado-joseph disease 11.3
10 sleep disorder 11.2
11 persistent genital arousal disorder 10.8
12 periodic limb movement disorder 10.5
13 neuropathy 10.3
14 sphenoorbital meningioma 10.2 DRD2 DRD3
15 teratoma with malignant transformation 10.2 DRD2 DRD3
16 intracranial cavernous angioma 10.1 DRD2 SLC6A3
17 kidney disease 10.1
18 attention deficit-hyperactivity disorder 10.1
19 splenic abscess 10.1 DRD2 SLC6A3
20 intracranial aneurysm 10.1 DRD2 DRD3
21 schizophrenia 10.1
22 narcolepsy 10.1
23 headache 10.1
24 irritable bowel syndrome 10.1
25 hypocalcemia, autosomal dominant 2 10.1 ATXN3 SLC6A3
26 aortic valve disease 2 10.1 BTBD9 DRD2 SLC6A3
27 pyromania 10.1 DRD2 DRD3 SLC6A3
28 18p deletion syndrome 10.1 DRD2 SLC6A3
29 transmitted_by 10.1 DRD2 DRD3 SLC6A3
30 cecal benign neoplasm 10.0 DRD2 DRD3 SLC6A3
31 mucinous adenocarcinoma 10.0 DRD2 DRD3 SLC6A3
32 cavernous hemangioma 10.0 DRD2 DRD3 SLC6A3
33 hypereosinophilic syndrome 10.0 DRD2 DRD3 SLC6A3
34 migraine with aura 10.0
35 tremor 10.0
36 tooth disease 10.0
37 impulse control disorder 10.0
38 essential tremor 10.0
39 charcot-marie-tooth disease 10.0
40 diabetic neuropathy 10.0
41 retinoblastoma 10.0 DRD2 DRD3 SLC6A3
42 lower gum cancer 10.0 HCRT SLC6A3
43 chronic conjunctivitis 10.0 DRD2 DRD3 SLC6A3
44 myotonic dystrophy 10.0
45 cerebrovascular disease 10.0
46 bruxism 10.0
47 pathological gambling 10.0
48 polyneuropathy 10.0
49 ataxia 10.0
50 sleep apnea 10.0

Graphical network of the top 20 diseases related to Restless Legs Syndrome:



Diseases related to Restless Legs Syndrome

Symptoms & Phenotypes for Restless Legs Syndrome

UMLS symptoms related to Restless Legs Syndrome:


back pain, headache, pain, sciatica, seizures, sleep disturbances, syncope, tremor, chronic pain, vertigo/dizziness, excessive daytime somnolence, sleeplessness

MGI Mouse Phenotypes related to Restless Legs Syndrome:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.23 ATXN3 BTBD9 DRD2 DRD3 HCRT SLC11A2

Drugs & Therapeutics for Restless Legs Syndrome

Drugs for Restless Legs Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 244)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved Phase 4,Phase 3 1994-09-7, 94-09-7 2337
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
3
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 60142-96-3 3446
4
Aspirin Approved, Vet_approved Phase 4,Phase 2 50-78-2 2244
5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
6
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
7
Ropinirole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 91374-20-8, 91374-21-9 5095 497540
8
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
9
Pramipexole Approved, Investigational Phase 4,Phase 3,Phase 2 104632-26-0 59868 119570
10
Topiramate Approved Phase 4 97240-79-4 5284627
11
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 148553-50-8 5486971
12
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2 52485-79-7 40400 644073
13
Ticlopidine Approved Phase 4,Phase 3 55142-85-3 5472
14
Amitriptyline Approved Phase 4 50-48-6 2160
15
Donepezil Approved Phase 4 120014-06-4 3152
16
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
17
Memantine Approved, Investigational Phase 4 19982-08-2 4054
18
Propranolol Approved, Investigational Phase 4 525-66-6 4946
19
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
20
Rizatriptan Approved Phase 4 145202-66-0, 144034-80-0 5078
21
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
22
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
23
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
24 tannic acid Approved, Nutraceutical Phase 4,Phase 3
25
Clopidogrel Approved, Nutraceutical Phase 4,Phase 3,Phase 2 120202-66-6, 113665-84-2 60606
26
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 2,Phase 3 67-97-0 6221 10883523 5280795
27 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Dopamine agonists Phase 4,Phase 3,Phase 2,Phase 1
29 N 0437 Phase 4,Phase 3,Phase 2
30 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
32 Anti-Anxiety Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1
34 Antimanic Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1
36 calcium channel blockers Phase 4,Phase 3,Phase 2,Phase 1
37 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
38 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
39 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
40 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Phase 1
41 GABA Agents Phase 4,Phase 3,Phase 1
42
gamma-Aminobutyric Acid Phase 4,Phase 3,Phase 1 56-12-2 119
43 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
44 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
45 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Hormones Phase 4,Phase 3
47 Methylprednisolone acetate Phase 4
48 Methylprednisolone Hemisuccinate Phase 4
49 Prednisolone acetate Phase 4
50 Prednisolone hemisuccinate Phase 4

Interventional clinical trials:

(show top 50) (show all 206)
id Name Status NCT ID Phase
1 Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome Unknown status NCT01823770 Phase 4
2 Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome Unknown status NCT02424695 Phase 4
3 12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome Completed NCT00373542 Phase 4
4 Long-term Study Of Ropinirole In Restless Legs Syndrome Completed NCT00329602 Phase 4
5 Post-marketing Study of Gabapentin Enacarbil to Evaluate the Effect in Restless Leg Syndrome (RLS) Patients With Moderate Renal Impairment Completed NCT01981941 Phase 4
6 Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy Completed NCT01245777 Phase 4
7 Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome Completed NCT02025608 Phase 4
8 Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS) Completed NCT00472199 Phase 4
9 Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome Post Marketing Commitment Study Completed NCT01668667 Phase 4
10 Efficacy and Safety Study of Topiramate to Treat Restless Legs Syndrome Completed NCT00200941 Phase 4
11 Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome Completed NCT01455012 Phase 4
12 SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole Completed NCT00344994 Phase 4
13 Switching From Oral Dopamine Agonists to Rotigotine Completed NCT01976871 Phase 4
14 A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS Completed NCT00349531 Phase 4
15 A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS Completed NCT00375284 Phase 4
16 Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances Completed NCT00356096 Phase 4
17 Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo Completed NCT00334048 Phase 4
18 An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS Recruiting NCT02560766 Phase 4
19 An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS Recruiting NCT02633683 Phase 4
20 Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease Recruiting NCT03063190 Phase 4
21 A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients Recruiting NCT03053427 Phase 4
22 Quality Improvement and Practice Based Research in Neurology Using the EMR Enrolling by invitation NCT02670161 Phase 4
23 Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease Not yet recruiting NCT03082755 Phase 4
24 Migraine Prophylaxis With Clopidogrel Trial Not yet recruiting NCT02938182 Phase 4
25 Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome Terminated NCT02117076 Phase 4
26 Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome Withdrawn NCT00584246 Phase 4
27 Butrans for Treatment of Restless Legs Syndrome Withdrawn NCT02138357 Phase 4
28 RCT Comparing Standard Cannula Delivered FS, UGFS and ClariVein® in the Management of SVI Withdrawn NCT02010437 Phase 4
29 Effects of Cognitive-Behavioral Therapy on Sleep Disturbance in Peritoneal Dialysis Patients Unknown status NCT00155441 Phase 3
30 Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients Completed NCT00806026 Phase 3
31 Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome) Completed NCT00256854 Phase 3
32 Bupropion and Restless Legs Syndrome Completed NCT00621517 Phase 2, Phase 3
33 Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome Completed NCT00197080 Phase 3
34 RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole Completed NCT00314860 Phase 3
35 An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome Completed NCT00263068 Phase 3
36 Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome Completed NCT00135993 Phase 3
37 Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS) Completed NCT01569464 Phase 3
38 A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS) Completed NCT00225862 Phase 3
39 Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS) Completed NCT00367822 Phase 3
40 Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance Completed NCT00991276 Phase 3
41 Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome Completed NCT00355641 Phase 3
42 A Sleep Lab Trial to Investigate the Efficacy and Safety of Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome Completed NCT00275236 Phase 3
43 Phase 3 Open-label Extension Trial With Rotigotine in Idiopathic Restless Legs Syndrome Subjects Completed NCT00498108 Phase 3
44 Study of SPM 962 in Patients With Restless Legs Syndrome (RLS) Completed NCT01084551 Phase 3
45 Sequential Compression Devices for Treatment of Restless Legs Syndrome Completed NCT00479531 Phase 3
46 Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome Completed NCT00136045 Phase 3
47 XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome. Completed NCT00333359 Phase 3
48 Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS) Completed NCT00654498 Phase 3
49 Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS) Completed NCT00133198 Phase 3
50 A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome Completed NCT00363857 Phase 3

Search NIH Clinical Center for Restless Legs Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: restless legs syndrome

Genetic Tests for Restless Legs Syndrome

Anatomical Context for Restless Legs Syndrome

MalaCards organs/tissues related to Restless Legs Syndrome:

39
Lung, Heart, Brain, Testes, Kidney, Liver, Spinal Cord

Publications for Restless Legs Syndrome

Articles related to Restless Legs Syndrome:

(show top 50) (show all 745)
id Title Authors Year
1
Sleep Disorders, Restless Legs Syndrome, and Uremic Pruritus: Diagnosis and Treatment of Common Symptoms in DialysisA Patients. ( 27693261 )
2017
2
Prevalence of restless legs syndrome during detoxification from alcohol and opioids. ( 28017182 )
2017
3
Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor Use as a Predictor of a Diagnosis of Restless Legs Syndrome. ( 27427838 )
2016
4
Rotigotine's effect on PLM-associated blood pressure elevations in restless legs syndrome: An RCT. ( 27164714 )
2016
5
Depth and Distribution of Symptoms in Restless Legs Syndrome/Willis-Ekbom Disease. ( 27655450 )
2016
6
Dopaminergic treatment of restless legs syndrome in spinal cord injury patients with neuropathic pain. ( 28053765 )
2016
7
Restless Legs Syndrome Following Lung Transplantation: Prevalence and Relationship With Tacrolimus Exposure. ( 27207403 )
2016
8
Influence of high altitude on periodic leg movements during sleep in individuals with restless legs syndrome and healthy controls: A pilot study. ( 27915206 )
2016
9
Pain, opioids, and sleep: implications for restless legs syndrome treatment. ( 27964861 )
2016
10
In search of alternatives to dopaminergic ligands for the treatment of restless legs syndrome: iron, glutamate, and adenosine. ( 27899234 )
2016
11
Restless Legs Syndrome in a Nigerian Elderly Population. ( 27070251 )
2016
12
Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation. ( 27539027 )
2016
13
Efficacy of gabapentin enacarbil in adult patients with severe primary restless legs syndrome. ( 27198947 )
2016
14
Psychiatric Comorbidities in Restless Legs Syndrome. ( 27019065 )
2016
15
Association of Restless Legs Syndrome with Incident Parkinson Disease. ( 27923428 )
2016
16
Restless Bladder in an Elderly Woman: An Unusual Feature or a Variant of Restless Legs Syndrome? ( 27629973 )
2016
17
Zolpidem Induced Sleep-related Eating and Complex Behaviors in a Patient with Obstructive Sleep Apnea and Restless Legs Syndrome. ( 27489385 )
2016
18
Special issue: Advances in scientific understanding of the restless legs syndrome (RLS) (aka: Willis Ekbom disease (WED): Introduction: Towards a better understanding of the science of RLS/WED. ( 27894926 )
2016
19
Is There an Association between Restless Legs Syndrome and Urticaria? ( 27134503 )
2016
20
The Effect of Gabapentin Enacarbil on Quality of Life and Mood Outcomes in a Pooled Population of Adult Patients with Moderate-to-Severe Primary Restless Legs Syndrome. ( 27067343 )
2016
21
Restless Legs Syndrome and Depression: Effect Mediation by Disturbed Sleep and Periodic Limb Movements. ( 27526989 )
2016
22
Prevalence of Restless Legs Syndrome in Patients with Inflammatory Bowel Disease. ( 28035549 )
2016
23
Does frequency of restless legs syndrome and poor sleep quality increase with age in irritable bowel syndrome? ( 27624325 )
2016
24
Do women with restless legs syndrome have less bone loss? ( 27022181 )
2016
25
Relationship between quality of life and restless legs syndrome among a community-dwelling population in Japan. ( 27110114 )
2016
26
Restless Legs Syndrome: Current Concepts about Disease Pathophysiology. ( 27536462 )
2016
27
Restless legs syndrome. ( 27481386 )
2016
28
Higher nocturnal systolic blood pressure in patients with restless legs syndrome compared with patients with insomnia. ( 27908587 )
2016
29
Evaluation of neurodegeneration through visual evoked potentials in restless legs syndrome. ( 27053144 )
2016
30
Augmentation and impulsive behaviors in restless legs syndrome: Coexistence or association? ( 27956569 )
2016
31
Effect of restless legs syndrome on blood pressure: is it sleep disturbance? ( 28057493 )
2016
32
A TRAPPC6B splicing variant associates to restless legs syndrome. ( 27569842 )
2016
33
Plasma apelin level in patients with restless legs syndrome and its association with periodic leg movements. ( 27193873 )
2016
34
Relationship between primary restless legs syndrome and migraine with aura. ( 27523456 )
2016
35
Achievements, challenges, and future perspectives of epidemiologic research in restless legs syndrome (RLS). ( 27567163 )
2016
36
Outcomes of long-term iron supplementation in pediatric restless legs syndrome/periodic limb movement disorder (RLS/PLMD). ( 27282843 )
2016
37
The Effect of Stretching Exercises on Severity of Restless Legs Syndrome in Patients on Hemodialysis. ( 27625757 )
2016
38
Optic nerve head, retinal nerve fiber layer and macular thickness analysis in restless legs syndrome. ( 27524286 )
2016
39
Gabapentin Enacarbil: A Review in Restless Legs Syndrome. ( 27146056 )
2016
40
Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with restless legs syndrome. ( 27546362 )
2016
41
Deep brain stimulation (DBS) for severe restless legs syndrome: therapeutic and physiologic considerations. ( 27964862 )
2016
42
Pregabalin for the Treatment of Restless Legs Syndrome. ( 27091870 )
2016
43
Somatic and neuropsychiatric comorbidities in pediatric restless legs syndrome: A systematic review of the literature. ( 27519964 )
2016
44
Increased frequency and severity of restless legs syndrome in patients with neuromyelitis optica spectrum disorder. ( 26847984 )
2016
45
Clinical and polysomnographic features of patients with Restless Legs Syndrome. ( 27183938 )
2016
46
Restless legs syndrome mimicking S1 radiculopathy. ( 27837576 )
2016
47
Targinact for restless legs syndrome. ( 27079737 )
2016
48
Restless Legs Syndrome in Patients with Hypertension and Diabetes Mellitus. ( 27147785 )
2016
49
Do periodic leg movements differ between restless legs syndrome patients with low versus normal iron stores? ( 28065401 )
2016
50
World Association of Sleep Medicine (WASM) 2016 standards for recording and scoring leg movements in polysomnograms developed by a joint task force from the International and the European Restless Legs Syndrome Study Groups (IRLSSG and EURLSSG). ( 27890390 )
2016

Variations for Restless Legs Syndrome

Expression for Restless Legs Syndrome

Search GEO for disease gene expression data for Restless Legs Syndrome.

Pathways for Restless Legs Syndrome

Pathways related to Restless Legs Syndrome according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
2 10.55 DRD2 DRD3
3 10.4 FTMT SLC11A2 TFRC
4 10.03 SLC11A2 TFRC

GO Terms for Restless Legs Syndrome

Cellular components related to Restless Legs Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.17 DRD2 DRD3 PCDHA3 PTPRD SLC11A2 SLC6A3

Biological processes related to Restless Legs Syndrome according to GeneCards Suite gene sharing:

(show all 35)
id Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.76 DRD2 DRD3 SLC6A3
2 negative regulation of protein kinase B signaling GO:0051898 9.67 DRD2 DRD3
3 positive regulation of cytokinesis GO:0032467 9.66 DRD2 DRD3
4 positive regulation of multicellular organism growth GO:0040018 9.66 DRD2 SLC6A3
5 long-term memory GO:0007616 9.65 BTBD9 DRD2
6 negative regulation of blood pressure GO:0045776 9.65 DRD2 DRD3
7 response to morphine GO:0043278 9.65 DRD2 DRD3
8 cellular iron ion homeostasis GO:0006879 9.65 FTMT SLC11A2 TFRC
9 negative regulation of adenylate cyclase activity GO:0007194 9.64 DRD2 DRD3
10 response to amphetamine GO:0001975 9.64 DRD2 DRD3
11 arachidonic acid secretion GO:0050482 9.63 DRD2 DRD3
12 modulation of synaptic transmission GO:0050804 9.63 BTBD9 DRD2
13 regulation of dopamine secretion GO:0014059 9.62 DRD2 DRD3
14 temperature homeostasis GO:0001659 9.62 DRD2 HCRT
15 behavioral response to cocaine GO:0048148 9.61 DRD2 DRD3
16 dopamine receptor signaling pathway GO:0007212 9.61 DRD2 DRD3
17 response to cocaine GO:0042220 9.61 DRD2 DRD3 SLC6A3
18 synaptic transmission, dopaminergic GO:0001963 9.6 DRD2 DRD3
19 iron ion transport GO:0006826 9.59 FTMT SLC11A2
20 dopamine metabolic process GO:0042417 9.58 DRD2 DRD3
21 positive regulation of renal sodium excretion GO:0035815 9.57 DRD2 DRD3
22 negative regulation of protein secretion GO:0050709 9.56 DRD2 DRD3
23 G-protein coupled receptor internalization GO:0002031 9.55 DRD2 DRD3
24 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.54 DRD2 DRD3
25 adenohypophysis development GO:0021984 9.52 DRD2 SLC6A3
26 multicellular organismal iron ion homeostasis GO:0060586 9.51 BTBD9 SLC11A2
27 regulation of cAMP metabolic process GO:0030814 9.49 DRD2 DRD3
28 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.46 DRD2 DRD3
29 locomotory behavior GO:0007626 9.46 DRD2 DRD3 MEIS1 SLC6A3
30 negative regulation of dopamine receptor signaling pathway GO:0060160 9.4 DRD2 DRD3
31 acid secretion GO:0046717 9.37 DRD2 DRD3
32 response to histamine GO:0034776 9.32 DRD2 DRD3
33 regulation of locomotion involved in locomotory behavior GO:0090325 9.26 DRD2 DRD3
34 response to iron ion GO:0010039 9.13 DRD2 SLC11A2 SLC6A3
35 prepulse inhibition GO:0060134 8.8 DRD2 DRD3 SLC6A3

Molecular functions related to Restless Legs Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.43 DRD2 DRD3 SLC6A3
2 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.16 DRD2 DRD3
3 dopamine neurotransmitter receptor activity GO:0004952 8.96 DRD2 DRD3
4 dopamine binding GO:0035240 8.8 DRD2 DRD3 SLC6A3

Sources for Restless Legs Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....